REGULATORY

MHLW Sees No Major Problem with Current Rules for Low-Price Products, Chuikyo Questions Price Negotiation Process

November 12, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s key reimbursement policy council on November 8 reviewed current rules surrounding low-priced drugs, including the price-maintenance system for essential medicines and special re-pricing for unprofitable products, but with the health ministry seeing no major issues on the pricing front,…

To read the full story

Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019

REGULATORY

MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…